IMVARIA Showcases AI Diagnostic Service for Lung Disease at ATS 2025

IMVARIA has presented its AI-powered diagnostic service, Fibresolve, at the ATS 2025 Conference, announced in a press release. Fibresolve is the first FDA-authorized AI adjunctive diagnostic service for lung fibrosis, designed to assist pulmonologists in diagnosing Interstitial Lung Disease (ILD) and Idiopathic Pulmonary Fibrosis (IPF).

The service, which integrates seamlessly into existing clinical workflows, was developed by medical doctors with software engineering expertise. It aims to provide pulmonologists with AI-supported diagnostic evaluations without the need for complex system installations. Clinical data from its use across the U.S. was presented by experts from Harvard's Mass General Hospital.

In addition to Fibresolve, IMVARIA also showcased two other AI solutions at the conference: ScreenDx, an FDA-cleared tool for assessing interstitial lung findings, and Bronchosolve, an investigational tool for evaluating lung nodules. These presentations underscore IMVARIA's commitment to advancing AI-driven diagnostic tools in the field of pulmonary medicine.